Aethlon Medical (NASDAQ:AEMD) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright lowered their price target on Aethlon Medical from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, June 24th.

Aethlon Medical Price Performance

Shares of NASDAQ:AEMD traded down $0.05 during trading on Thursday, reaching $0.51. 2,069,070 shares of the stock were exchanged, compared to its average volume of 2,251,762. Aethlon Medical has a 1-year low of $0.24 and a 1-year high of $3.20. The stock has a fifty day moving average of $0.44 and a two-hundred day moving average of $1.02. The firm has a market cap of $7.12 million, a price-to-earnings ratio of -0.11 and a beta of 1.65.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.10. During the same period in the prior year, the company posted ($1.30) EPS. Sell-side analysts forecast that Aethlon Medical will post -1.13 EPS for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.